Ascendis Pharma A/S announced results from enliGHten, the Company’s open-label extension trial evaluating the long-term safety and efficacy of TransCon hGH as a once-weekly treatment for children and adolescents with growth hormone deficiency.
Coherus BioSciences, Inc., announced that effective September 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 109,000 shares of the common stock of the Company to six newly hired employees with a per share exercise price of $4.51, the closing trading price on the grant date.
Coherus BioSciences Announces New Employment Inducement Grants – September 23, 2023 Read More »
On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered in Guangzhou to participate in the YL201 Phase I/II Investigators Meeting hosted by Suzhou MediLink Therapeutics Co., Ltd.
Shanghai Henlius Biotech, Inc. announced that the new drug application for new indication of HANSIZHUANG in combination with drugs containing fluorouracil and platinum for the first-line treatment of patients with PD-L1 positive unresectable locally advanced/recurrent or metastatic ESCC, has been approved by the NMPA, providing a new treatment option for patients with ESCC.
Recent drug approvals have shone a light on the role that patient advocacy groups can play in the regulatory process—but some experts have questions about the ethics of this influence.
Upcoming NurOwn Adcomm Highlights Regulatory Role for Patient Advocates Read More »
Sobre la toma de decisiones a partir de los riesgos de las intervenciones de salud
Escepticemia por Gonzalo Casino | Ayudas para decidir Read More »
Un motivo de celebración y de alegría compartida
Los invitamos a dejar sus comentarios | IntraMed cumple 26 años junto a usted Read More »
Leaders of the Coalition of Kaiser Permanente Unions announced on Friday that over 75,000 members will strike from Oct. 4 to Oct. 6 if labor and management cannot agree to new contract terms.
CMS Deputy Administrator Jon Blum signaled regulators could increasingly crack down on bad actors in the MA program, which now covers more than half of Medicare seniors.
CMS to get ‘tougher’ on Medicare Advantage, official promises Read More »
Unos científicos han desarrollado un nuevo modelo de la enfermedad de Alzheimer para aclarar el papel de uno de sus aparentes factores de riesgo: el virus del herpes. El trabajo lo ha realizado un equipo que incluye a María Jesús Bullido y a Blanca Salgado, ambas del Ce …
¿Está el virus del herpes simple 1 implicado en la enfermedad de Alzheimer? Read More »
